Loading
Distinct shells carrying a filed role for this person — not every shell they have ever touched.
Of those vehicles, the ones that closed a merger.
Announced but not closed, and still hunting.
No closed vehicle here has both a stored price and a filed trust value to score it against.
1 vehicle on file, newest listing first
none appears on more than one
Spencer Gerrol is the Founder and CEO of SPARK Neuro, a neuroscience technology company that develops AI-enabled, FDA-cleared EEG brain scan devices and services for objective neurological assessments, primarily targeting dementia screening and diagnosis. He also serves as an Independent Director on the board of Soren Acquisition Corp. (NASDAQ: SORNU), a healthcare-focused SPAC that closed its $253 million initial public offering in January 2026, with units consisting of one Class A ordinary share and one-third of one redeemable warrant. Through his membership interests in Soren Acquisition's sponsor, Gerrol received an indirect interest in 50,000 founder shares. The SPAC is led by CEO Arghavan Di Rezze and CFO Jamie Weber, with fellow board members Marc Mazur and Charles N. Khan III, and advisors Peter Ondishin and Nicholas Shekerdemian. Soren Acquisition is focused on completing a business combination with an attractive target within the healthcare industry.
Gerrol founded SPARK Neuro in 2016 or 2017, building on his earlier venture, SPARK Experience, a design agency founded in 2009 where his team began neuroscience research in 2013 using machine learning for consumer insights, including high-profile studies on the 2016 U.S. elections analyzing brain responses of Trump and Hillary supporters. After selling SPARK Experience to Motivate Design, he launched SPARK Neuro to commercialize biometric technology for measuring subconscious attention and emotion via EEG, GSR, facial tracking, and eye movement. Early traction came from neuromarketing clients such as Paramount Pictures, NBC, Procter & Gamble, GM, Netflix, and Toyota, and the company later evolved into healthcare applications through partnerships with Mayo Clinic and Johns Hopkins. SPARK Neuro has raised over $35 million in funding, including a $14 million Series A in August 2018 led by Peter Thiel and Thiel Capital with participation from Accel, Founders Fund, Sequoia Capital, GV (Google Ventures), General Catalyst, Will Smith, and others, followed by a $10 million round in February 2023 with investors including Afore Capital, Greycroft, RTP Global, Y Combinator, Village Global, and Dreamers VC. The company has also secured significant government funding, including a $2.5 million Phase II SBIR award from the NIH in 2024 to validate its SPARK Scan EEG-based neurodiagnostic platform for assessing cognitive impairment and Alzheimer's Disease. Previously in his career, Gerrol worked at Human Factors International, leveraging his background in cognitive psychology and human factors.
With over 18 years of experience in cognitive science, Gerrol has been recognized as a World Economic Forum Global Shaper and was honored at the White House for founding one of the top 100 companies started by young entrepreneurs. He has delivered keynote presentations at Google, TED, the United Nations, the White House, the Pentagon, Cannes Lions, and the Advertising Research Foundation, and has been featured in CNN, The Washington Post, ABC News, Forbes, The Wall Street Journal, and Ad Week. He is based in Los Angeles, California, where he lives with his wife Rachel Gerrol, Co-Founder and CEO of NEXUS, and their two sons. At SPARK Neuro, he leads a team of neuroscientists, neurologists, engineers, and AI experts dedicated to making brain health measurement universal, accessible, and part of standard care, with a vision that caring for your brain becomes as routine as measuring blood pressure.
This record is keyed to SEC CIK 0002091124 — the identifier this person files under in their own name. Every vehicle above is a filing made under that CIK, so “the same person on two shells” is a fact about an SEC identifier rather than about a name that happens to match.
Roles are the strings the filings used, in the order they were filed. Nothing on this page ranks them, infers seniority, or offers a reason why any two of these names recur — a recurrence is a count, and the filings that produced it are linked beside every row. We also hold 8 institutional-holder rows on these vehicles, under 7 distinct name strings, and none of them is counted across vehicles: that table has no CIK column, and matching holders by name would merge firms that are not the same firm.